ProfileGDS5678 / 1460611_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.239779
GSM967853U87-EV human glioblastoma xenograft - Control 22.215749
GSM967854U87-EV human glioblastoma xenograft - Control 32.219089
GSM967855U87-EV human glioblastoma xenograft - Control 42.165449
GSM967856U87-EV human glioblastoma xenograft - Control 52.167819
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.272959
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.233079
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.196099
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.187089
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.206869
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.202819
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.190119
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.211689
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.207949